Top Markets
Coin of the day
PhoenixBio Co., Ltd. PhoenixBio Co., Ltd.

PhoenixBio Co., Ltd.

6190
Rang in Aktien #32813
PhoenixBio Co., Ltd. delivers specialized contract research services to support... PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.
Aktienkurs
$2.22
Marktkapitalisierung
$9.03M
Veränderung (1 Tag)
-3.13%
Veränderung (1 Jahr)
-21.92%
Land
JP
Handel PhoenixBio Co., Ltd. (6190)

Kategorie

Dividendenrendite-Verlauf für PhoenixBio Co., Ltd. (6190)
Dividendenrendite (TTM) von PhoenixBio Co., Ltd. (Aktienkürzel: 6190) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für PhoenixBio Co., Ltd. (6190) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber